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APOBEC3 family DNA cytosine deaminases provide
overlapping defenses against pathogen infections.
However,most viruses have elaborate evasionmech-
anisms such as the HIV-1 Vif protein, which subverts
cellular CBF-b and a polyubiquitin ligase complex
to neutralize these enzymes. Despite advances in
APOBEC3 and Vif biology, a full understanding of
this direct host-pathogen conflict has been elusive.
We combine virus adaptation and computational
studies to interrogate the APOBEC3F-Vif interface
and build a robust structural model. A recurring
compensatory amino acid substitution from adapta-
tion experiments provided an initial docking con-
straint, and microsecond molecular dynamic simula-
tions optimized interface contacts. Virus infectivity
experiments validated a long-lasting electrostatic
interaction between APOBEC3F E289 and HIV-1 Vif
R15. Taken together with mutagenesis results, we
propose a wobble model to explain how HIV-1 Vif
has evolved to bind different APOBEC3 enzymes
and, more generally, how pathogens may evolve to
escape innate host defenses.
INTRODUCTION
The APOBEC3 (A3) family of DNA cytosine deaminases com-
prises a powerful arm of the innate immune defense system
in mammals. These enzymes provide overlapping protection
against highly diverse DNA-based pathogens including trans-Cell Reposable elements and viruses (reviewed by Desimmie et al.,
2014 and Harris and Dudley, 2015). For instance, four A3
enzymes, APOBEC3D (A3D), APOBEC3F (A3F), APOBEC3G
(A3G), and APOBEC3H (A3H), each act to suppress HIV type 1
(HIV-1) replication by packaging into newly synthesized viral par-
ticles, directly interferingwith reverse transcription, andmutating
nascent cDNA cytosines to uracils (reviewed by Desimmie et al.,
2014 and Harris and Dudley, 2015). The latter become viral
genomic strand guanine-to-adenine (G-to-A) mutations.
To counteract the deleterious effects of these enzymes, HIV-1
encodes a protein called virion infectivity factor (Vif) that scaf-
folds the formation of an E3 ubiquitin ligase complex that directly
binds restrictive A3 enzymes and targets them for proteasome-
mediated degradation (reviewed by Desimmie et al., 2014 and
Harris and Dudley, 2015). The Vif protein of primate lentiviruses
HIV-1, HIV-2, and simian immunodeficiency virus (SIV) has
evolved to dimerize with the transcription cofactor CBF-b (An-
derson and Harris, 2015 and references therein). This complex
enables Vif to additionally bind ELOC and CUL5 and, through
these partners, also to ELOB and RBX2. Upon the addition of
NEDD8 to CUL5, this E3 ligation assembly becomes activated
to transfer ubiquitin from an E2 enzyme to Vif-engaged A3
substrates. Proteomic approaches have been instrumental in
identifying Vif ligase components, and genetic studies have
demonstrated the essential nature of all of the subunits. A crystal
structure of HIV-1 Vif-CBF-b-ELOB-ELOC-CUL5 has helped to
rationalize prior results (Guo et al., 2014).
A3F is a notable HIV-1 restriction factor for multiple reasons.
First, overexpression causes a dose-responsive drop in the in-
fectivity of Vif-defective viruses and inflicts mutations in a GA-to-
AA context (minus strand TC-to-TT) (Bishop et al., 2004; Lidda-
ment et al., 2004; Wiegand et al., 2004; Zheng et al., 2004).
Second, knockout and knockdown experiments demonstrateports 13, 1781–1788, December 1, 2015 ª2015 The Authors 1781
that endogenous levels of this enzyme contribute to HIV-1 restric-
tion and hypermutation in a CD4-positive T cell line and, together
with A3D and A3H, account for the GA-to-AA hypermutation
signature observed in patient-derived viral sequences (Refsland
et al., 2012). Third, HIV-1 restriction activity is conserved between
humanand rhesusmacaqueA3F (Hultquist et al., 2011;Virgenand
Hatziioannou, 2007; Zennou andBieniasz, 2006). Fourth, both Vif-
binding andDNAcytosinedeaminase activities residewithin a sin-
gle zinc-coordinating domain, unlike A3G where these activities
are split between the N- and C-terminal domains, respectively
(Hache´ et al., 2005; Russell et al., 2009). Fifth, multiple high-reso-
lution structures and mutagenesis studies have indicated that the
Vif-binding surfaceof A3F is similar to that of A3DandAPOBEC3C
(A3C), but at least partially distinct from those of A3Gand A3H (Al-
bin et al., 2010b; Bohn et al., 2013; Kitamura et al., 2012; Kouno
et al., 2015; Land et al., 2014; Russell et al., 2009; Schro¨felbauer
et al., 2006; Siu et al., 2013; Smith and Pathak, 2010). Sixth,
HIV-1 Vif separation-of-function mutants demonstrated the im-
portance of A3F in humanized mouse models for viral pathogen-
esis (Krisko et al., 2013; Sato et al., 2014). Finally, in long-term
cell culture experiments, A3F is sufficiently potent to suppress
Vif-deficient HIV-1 replication and select for Vif restoration-of-
function mutants (Albin et al., 2010a). This final point is important
because it indicates that HIV-1 requires Vif function in order
to antagonize A3F and preserve the capacity to replicate. It
also implies that HIV-1 cannot easily evolve a Vif-independent
mechanism to evade A3F, which further distinguishes this
enzyme frommultiple Vif-independent mechanisms that the virus
may employ to escape A3G restriction (Hache´ et al., 2008). In
other words, the A3F-Vif interaction is essential from an HIV-1
perspective.
Despite these and other advances in the overall understanding
of Vif andA3 biology, it is still not clear howVif actually binds to an
A3substrate.Here,we leverage the selective potential of A3Fand
virus adaptation studies to identify A3F-interacting amino acid
residues within Vif. A recurring genetic contact provided an an-
chor point for docking the two proteins and deriving a physical
interaction model. Molecular dynamic (MD) simulations led to
a refined Vif-A3F interaction model that predicted a durable
anchoring electrostatic interaction. Charge-reversing substitu-
tions in either A3F (E289K) or Vif (R15E) abrogated the interaction,
but the combined amino acid charge changes enabled the inter-
action to be restored as evidenced by A3F degradation and high
viral infectivity. Genetic gain-of-function data were therefore
instrumental in both informing the initial model as well as vali-
dating the refined model. Our Vif-A3F interaction model also
explains prior loss-of-function observations. Overall, our multi-
disciplinary approachhas yieldedacomprehensive three-dimen-
sional structural model of this critical pathogen-host interface
and also inspired a general wobble model to explain the rapid
evolution of this and other pathogen-host interactions.
RESULTS
HIV-1 Adapts to Replicate in the Presence of
Vif-Resistant A3F
The lentiviral Vif protein is thought to have evolved to selectively
neutralize the A3 repertoire of cognate host species (reviewed by1782 Cell Reports 13, 1781–1788, December 1, 2015 ª2015 The AutDesimmie et al., 2014 and Harris and Dudley, 2015). Conse-
quently, virus replication is typically restricted by A3s of non-
cognate species. For example, the replacement of human A3F
(huA3F) residues E324 with the corresponding rhesus macaque
A3F (rhA3F) residues K324 renders the human enzyme resistant
to degradation by HIV-1 Vif (Albin et al., 2010b; Land et al., 2014;
below). We therefore hypothesized that cells expressing this
simianized form of huA3F or the naturally restrictive rhA3F (Hult-
quist et al., 2011; Virgen and Hatziioannou, 2007) would provide
selective pressure to force HIV-1 to adapt by making compensa-
tory changes in Vif, analogous to the way that ancestral SIV
strains may have adapted in order to transmit into the human
population (Figure 1A).
To test this hypothesis, HIV-1IIIB and HIV-1LAI-GFP stocks
were used in graded selection experiments with each passage
containing increasing proportions of SupT11 clones stably ex-
pressing either huA3F QE323-324EK or rhA3F (i.e., permissive
T cells rendered non-permissive through stable expression of
these restrictive A3 enzymes). A3F levels in low-expressing
T cell lines approximated those in primary CD4-positive T cells
(Land et al., 2014), whereas those in medium- and high-ex-
pressing lines were intentionally super-physiological (Figure 1B).
This approach allows viral sequence diversity to accumulate
while selecting for compensatory changes. In total, four
rounds of stepwise selection were performed, followed by four
additional rounds of MOI-controlled passages under 100%
non-permissive conditions to select high-fitness viruses (Exper-
imental Procedures).
Dozens of independent adapted viral populations were ob-
tained as evidenced by similar replication kinetics in permissive
SupT11 control cells and non-permissive A3F-expressing deriv-
atives. Adapted variants were identified by sequencing vif from
proviral DNA, and a clear hotspot emerged with Vif G71D domi-
nating both selective conditions (Figure 1C). Although other
amino acid substitutions occurred, none was as prominent as
Vif G71D and none apart from Vif G71D yielded a clear pheno-
type in the context of an otherwise clean molecular clone
(G71D data below and additional data not shown; the identities
of all amino acid changes occurring in two or more independent
cultures are listed in Figure 1C relative to previously implicated
interaction motifs in HIV-1 Vif).
HIV-1 Vif G71 Influences the Interaction with A3F
To determine whether HIV-1 Vif G71D overcomes restriction bar-
riers imposed by huA3F QE323-324EK and rhA3F, single-cycle
infectivity experiments were done with Vif G71D versus wild-
type huA3F, huA3F E324K, and rhA3F. As shown in Figure 2A,
G71D mutants displayed modest loss of function in neutralizing
wild-type huA3F, but gained significant activity against huA3F
E324K and rhA3F. Spreading infection data corroborated these
results as Vif G71D engineered into the parental HIV-1IIIB molec-
ular clone, with no other amino acid changes, became attenu-
ated in cells expressing medium and high levels of huA3F, but
clearly gained the capacity to replicate in the presence of
huA3F E324K (Figure 2B). Peak spreading infection titers did
not appear to be affected but a kinetic delay was observed, sug-
gesting that the single G71D change is sufficient to overcome re-
striction but not optimal for virus replication. Analogous resultshors
Figure 1. HIV-1 Adaptation to Vif-Resistant A3F
(A) A schematic depicting the co-culture selection strategy used to adapt HIV-1 to Vif-resistant A3F-expressing cells as the selective pressure. Viruses were
passaged stepwise approximately every 8–11 days from permissive to increasingly non-permissive cultures as shown. Upon completing a round of selection
from fully permissive to fully non-permissive cultures, portions of each culture were cycled back to the beginning of the process for another round of selection.
(B) Anti-A3F immunoblot of SupT11-derived T cell lines stably expressing huA3F, A3F QE323-324EK, or empty vector (relative protein expression levels as
follows: L, low; M, medium; H, high; VH, very high; and V, empty vector). A3F levels in HIV-1-infected primary T cell and H9 lysates are shown for comparison.
(C) Bar graphs indicating the number of independent times that each of the indicated HIV-1 IIIB or LAI Vif amino acid changes were observed. The x axis is a to-
scale depiction of Vif residues 1–192 with previously reported motifs indicated below for reference. In most instances, HIV-1IIIB and HIV-1LAI had the same amino
acid change at a given position with the exception of HIV-1IIIB E117K and HIV-1LAI D117N for both A3F QE323-324EK and rhA3F selective conditions (shown
explicitly in the figure).were obtained for spreading infection experiments with HIV-1 Vif
G71 versus D71 molecular clones in SupT11 cells stably ex-
pressing rhA3F (Figure S1).
Delineation of the Vif-A3F Interface
The gain-of-function amino acid substitution G71D selected in
adaptation experiments with both huA3F E324K and rhA3F sug-
gested that these two residues are physically interacting. This
possibility is consistent with the crystal structure of HIV-1 Vif
ligase complex, where G71 is located within a solvent-exposed
loop on the same surface as the a-helical D14-R15-M16-R17
motif previously implicated in interacting with A3F (Russell and
Pathak, 2007; Russell et al., 2009; Smith and Pathak, 2010; Fig-
ure 3A). It is also consistent with huA3F E324 being located
within the conserved a4 helix and likewise accessible for direct
interaction (Figure 3B). In addition, E324 is part of the larger
a3-a4 region of huA3F and rhA3F implicated by genetic studies
as interacting with HIV-1 Vif (Albin et al., 2010b; Kitamura et al.,
2012; Land et al., 2014; Russell and Pathak, 2007; Russell et al.,
2009; Smith and Pathak, 2010).
We therefore used HIV-1 Vif G71 and huA3F E324 as
anchoring points to generate a structural interaction model that
obeys physical constraints and best explains prior genetic
studies. The ClusPro protein-protein docking web server was
used to generate 20 Vif-huA3F interaction models, and one
model with Vif G71 and A3F E324 in close proximity was selectedCell Refor further computational studies (Figure 3C). In this model the
main chain amide of Vif G71 is within bonding distance of the
side chain of A3F E324 (3 A˚). Additional features of this model
are extensive interactions between the G71 loop and the DRMR
motif of HIV-1 Vif with the a3 and a4 helices of A3F. In particular,
Vif R15 is predicted to form a direct electrostatic interaction with
A3F E289 (Figure 3C).
To optimize the predicted Vif-huA3F interface, the docked
complex was subjected to three independent 1-ms MD simula-
tions (Figures 3D, S2, and S3; Movies S1, S2, and S3). The first
notable observation was the relative fragility of the interaction
between Vif G71 and huA3F E324, which was lost rapidly in
two of the simulations (persistence times of 70 and 1 ns inMovies
S1 and S2; inter-residue distances plotted in Figure S2). Second,
the electrostatic interaction between Vif R15 and huA3F E289
was stable through large proportions of each independent 1-ms
simulation (Movies S1, S2, and S3; inter-residue distances
plotted in Figure S3; representative pose in Figure 3D). More-
over, all three MD simulations arrived at a single preferred inter-
action conformation anchored by an interaction between Vif R15
and huA3F E289.
An additional appealing feature of these MD refinements was
an approximately 90 rotation in the Vif interaction to include a
hydrophobic pocket of huA3F between the a2 and a3 helices
(Figure 3D; Movie S2). Specifically, Vif W79, which is located in
the G71 loop, docked into the a2 and a3 hydrophobic pocketports 13, 1781–1788, December 1, 2015 ª2015 The Authors 1783
Figure 2. HIV-1 Vif G71D Enables Viral Infectivity in the Presence of
Vif-Resistant A3F
(A) Single-cycle infectivity data for Vif-null HIV-1IIIB produced in the presence of
huA3F, huA3F E324K, or rhA3F and the indicated amounts of Vif G71 (wild-
1784 Cell Reports 13, 1781–1788, December 1, 2015 ª2015 The Autof huA3F. This predicted interaction is concordant with prior
mutagenesis experiments, which had implicated this huA3F re-
gion in the Vif interaction (Kitamura et al., 2012). In addition,
this MD-optimized pose still maintains interactions between Vif
and the a3 and a4 regions of huA3F, including the electrostatic
interaction between Vif R15 and huA3F E289. Altogether, the
MD simulation-optimized Vif interaction model buries approxi-
mately 1,300 A˚2 surface area between the two proteins and in-
volves huA3F helices a2, a3, and a4, as well as the hydrophobic
pocket between a2 and a3 (Figure 3D; Movie S2).
Model Validation
MD simulations predicted a direct electrostatic interaction be-
tween Vif R15 and A3F E289 (Figures 3D, S2, and S3; Movies
S1, S2, and S3). Prior work showed that Vif R15A generated a
separation-of-function variant defective for huA3F degradation,
but not for A3Gdegradation, and also that huA3F E289K became
resistant to HIV-1 Vif-mediated degradation (Russell and Pathak,
2007; Russell et al., 2009; Smith and Pathak, 2010). Thus, we
predicted that reciprocal charge changes at these amino acid
positions in Vif and huA3F, respectively, would singly destroy
Vif degradation activity but together restore the functional inter-
action. Indeed, each of these charge-changing amino acid sub-
stitutions alone compromised Vif degradation function, but in
combination the capacity for HIV-1 Vif to degrade huA3F was
restored (Figure 4A). This result is evident through the decreased
huA3F band intensities in immunoblot images (indicating degra-
dation) and through significantly increased viral infectivity in sin-
gle-cycle infection experiments. Additionally, this predicted
gain-of-function pairing enabled HIV-1 with Vif E15 to undergo
a robust spreading infection in SupT11 cells stably expressing
the restrictive A3F K289 enzyme (Figure 4B). Taken together,
these data provide strong genetic evidence in support of a direct
physical interaction between Vif R15 and A3F E289 and the Vif-
huA3F interaction model derived above.
DISCUSSION
The Vif-A3F interaction is essential for HIV-1 pathogenesis in hu-
manized mice, rhesus macaques, and most likely also humans
(Desrosiers et al., 1998; Farrow et al., 2005; Krisko et al., 2013;
Rangel et al., 2009; Sato et al., 2014; Schmitt et al., 2010; Simon
et al., 2005). Here we used huA3F E324K and rhesus A3F (natu-
rally K324), which both resist degradation by HIV-1 Vif (Albin
et al., 2010b; Hultquist et al., 2011; Virgen and Hatziioannou,
2007; Zennou and Bieniasz, 2006), as tools to select for viral var-
iants that regain the capacity to replicate in long-term cell culture
experiments. Vif G71D was the major adaptive change that
emerged in these studies and the only one that reconfirmedtype) or Vif D71 (adapted) expression constructs. Immunoblots are shown
below for Vif (anti-HA), A3F (anti-V5), and tubulin (anti-TUB).
(B) Spreading infection data are shown for HIV-1IIIB stocks with the indicated
Vif alleles in SupT11 clones expressing zero (empty vector), low, medium, or
high levels of huA3F or huA3F E324K.
(C) Anti-A3F immunoblot of SupT11-derived T cell lines stably expressing
huA3F or A3F E324K. Empty vector-transfected SupT11 clones V1 and V2 and
the non-permissive T cell line H9 are shown for comparison.
hors
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Figure 3. Vif-A3F Interaction Model
(A) A ribbon schematic of HIV-1 Vif highlighting
residues D14, R15, M16, R17, and G71. D14 is the
first residue of an a helix containing Vif residues
14–31, which includes the DRMR motif. Vif G71 is
located in a nearby loop on the same surface of the
structure (PDB: 4N9F). Vif is colored cyan and a
faded surface representation of CBF-b is shown in
green to facilitate visualization.
(B) A ribbon schematic shows the Vif-binding
domain of huA3F, highlighting the a3 and a4 heli-
ces and the position of residue E324 near the end
of the a4 helix (PDB: 4IOU).
(C) A model of the complex generated by docking
A3Fctd onto Vif. In this initial docked model, direct
interactions occur between A3F E324 and Vif G71
as well as A3F E289 and R15.
(D) An MD simulation-optimized model of the A3F-
Vif macromolecular complex. Residues E289 and
R15 form a strong persistent interaction, and resi-
dues within the Vif G71-containing loop are inter-
acting with A3F residues between helices a2 and
a3. See the main text for details.in infectivity experiments. This infectivity-restoring amino acid
change suggested that a new, stabilizing physical interaction
had been established between A3F K324 and Vif D71, and it
provided a critical constraint for docking studies. However,
structural optimization using MD simulations suggested that
the interaction between A3F E324 and Vif G71 is unlikely to be
robust in the wild-type setting, and instead revealed a consider-
ably more stable protein-protein interface dominated by a
persistent electrostatic interaction between A3F E289 and Vif
R15. Remarkably, the reciprocal charge changes of A3F E289K
and Vif R15E resulted in A3F degradation and HIV-1 infectivity
phenotypes similar to a wild-type scenario. These gain-of-func-
tion results provide strong genetic evidence in favor of A3F E289
and Vif R15 constituting an integral part of the physical interac-
tion. The best-fit model presented here provides a comprehen-
sive structural view of the A3F-Vif interaction and, by homology
modeling, also of the entire A3F-bound ubiquitin ligase complex
(Figure S5).
Prior mutagenesis studies have implicated multiple amino
acids in the interaction between huA3F and HIV-1 Vif (Albin
et al., 2010b; Kitamura et al., 2012; Land et al., 2014; Russell
and Pathak, 2007; Russell et al., 2009; Smith and Pathak,
2010). Most of these prior results can be re-interpreted using
our best-fit model and grouped into those that participateCell Reports 13, 1781–1788, Ddirectly or indirectly in the actual interac-
tion. Prior separation-of-function data
include A3F amino acid substitutions
C259K, IL262/3AA, S264D, and Y269A,
which are located between the a2 and
a3 helices, and E289K and E324K, which
are located on the solvent-exposed sur-
faces of the a3 and a4 helices, respec-
tively. Each of these A3F amino acid
substitutions confer resistance to Vif-
mediated degradation and do not affectthe enzyme’s HIV-1 restriction capabilities (Albin et al., 2010b;
Kitamura et al., 2012; Land et al., 2014; Russell and Pathak,
2007; Russell et al., 2009; Smith and Pathak, 2010; this study).
These A3F residues are all located within the interface of our
best-fit model, best highlighted by A3F E289 forming a persistent
electrostatic interaction with Vif R15.
On the Vif side of this interaction, separation-of-function mu-
tants fall into three clusters. Vif cluster 1 residues are located in
anahelix definedbyD14,R15,M16, andR17 (Russell andPathak,
2007; Russell et al., 2009; Schro¨felbauer et al., 2006; Smith and
Pathak, 2010). Our model indicates that this HIV-1 Vif helix forms
extensive electrostatic interactions with A3F a3 and a4 helices
(e.g., Vif R15 with A3F E289). Vif cluster 2 residues span the G71
loop region (residues G71–G82) (Figures 3C and S4). Our model
predicts that this aligns Vif W79 to dock with residues located be-
tween the a2 and a3 helices of A3F. Several single alanine substi-
tutions within this loop confer susceptibility to A3F-mediated re-
striction (e.g., E76A in Figure S4). Vif cluster 3 residues (H42,
H43, and Y44) are predicted to interact with amino acids located
between A3F a3 and a4 helices. Although this region of Vif clearly
mediates interactions with A3G (Kouno et al., 2015; Russell and
Pathak, 2007; Russell et al., 2009; Smith and Pathak, 2010), our
model suggests that these residues also may participate in the
Vif-A3F interaction. Overall, Vif clusters 1, 2, and 3 may combineecember 1, 2015 ª2015 The Authors 1785
Figure 4. HIV-1 Vif-A3F Interface Interactions Validated by Gain-of-
Function Viral Infectivity Experiments
(A) Single-cycle infectivity data for Vif-null HIV-1IIIB produced in the presence of
huA3F, huA3F E324K, or huA3F E289K and the indicated amounts of Vif R15
(wild-type) or Vif E15 expression constructs. Each histogram bar shows the
average infectivity from three independent experiments (mean ± SEM). Sta-
tistical significance was determined by two-way ANOVA followed by a post
hoc Bonferroni test to determine significance between or within testing groups
(p values of less than 0.05 were considered significant). Immunoblots are
shown below for virus-like particles (anti-A3F and anti-P24) and producer cell
lysates (anti-A3F, anti-Vif, and anti-TUB).
(B) Spreading infection data demonstrate that HIV-1 encoding Vif R15E rep-
licates on SupT11 that stably expresses A3F E289K, whereas HIV-1 IIIB Vif
cannot establish a productive infection in identical culture conditions. SupT11-
derived T cell lines used for these spreading infections have been stably
transfected with huA3F, A3F E289K, or a vector. A3F protein expression in H9
lysates is shown for comparison.
1786 Cell Reports 13, 1781–1788, December 1, 2015 ª2015 The Autto bind A3F, with clusters 1 and 2 forming essential interactions
and cluster 3 providing additional stabilizing contacts.
We propose a wobble model to explain the dynamic nature of
the Vif-A3 interaction (Figure 5). In this model, Vif forms a network
of interactionswith a givenA3substrate, suchasA3F. If the overall
interaction is destabilized, for instance, due to an immune escape
variation in Vif or a naturally occurring variation in a host A3
enzyme, a compensatory change in Vif can restore a fully func-
tional interaction. Such a compensatory change may occur at
the original interacting residue, nearby, or even at an edge of the
interface. In support of this idea, the negatively charged mutation
G71D was selected in multiple independent adaptation experi-
ments in order to counteract a positively charged E324K substitu-
tion in huA3F or the naturally occurring K324 in rhesus macaque
A3F, yet this interactionwasweak inMDsimulations.Onanevolu-
tionary timescale, an extensive series ofwobbles could enable the
Vif-A3 interface to drift to a completely different solvent-exposed
surface (Figure 5). This model provides an attractive explanation
for how HIV-1 Vif could have evolved to use distinct surfaces to
bind each of the restrictive human A3 enzymes (e.g., A3F and
A3G in Figure 5; data in this study; Albin et al., 2010b; Kitamura
et al., 2012; Kouno et al., 2015; Land et al., 2014; Ooms et al.,
2013; Refsland et al., 2014; Russell and Pathak, 2007; Russell
et al., 2009; Smith and Pathak, 2010). It also provides a molecular
explanation for the evolutionary theory known as the RedQueen’s
Hypothesis (Van Valen, 1973). Moreover, based on the relatively
facile cross-species adaptation of HIV-1 from huA3F- to rhesus
macaque A3F-expressing cells, this model accounts for how an
ancestral lentivirus may have adapted from a host with a simple
A3 repertoire (most non-primate mammals) to be able to replicate
in the presence of amore complex,multi-protein A3 repertoire, as
exists in modern primates including humans (Figure 5). This
wobble model also may explain the evolutionary dynamics of a
wide range of pathogen-host interactions.
EXPERIMENTAL PROCEDURES
Plasmids
The huA3F-matching NM_145298 and A3F QE323-324EK have been
described previously (Albin et al., 2010b; Liddament et al., 2004). Rhesus
A3F-matching NM_001042373.1 was provided by T. Hatziioannou (Aaron
Diamond AIDS Research Center [ADARC]) and cloned into a pcDNA3.1-
derived 33 hemagglutinin (HA) vector as described previously (Liddament
et al., 2004). A V5-tagged derivative of rhA3F was made by subcloning from
the 33HA vector as described previously (Albin et al., 2010b). Specific point
mutants were made by QuikChange site-directed mutagenesis (Stratagene).
Full-length proviral HIVIIIB and HIVLAI-GFP plasmids have been described, and
the HIVIIIB sequence is identical to EU541617 except for an A200C nucleotide
change to interrupt an atypical upstream open reading frame (Albin et al.,
2010b; Hache´ et al., 2008, 2009). Proviral mutant plasmid mutants were
assembled in a TOPO shuttle vector containing the vif-vpr region and then
subcloned back into the full-length context via the unique sites SwaI/SalI in
HIV-1IIIB or PshAI/SalI in HIV-1LAI-GFP.
Cell Culture
T cell lines were maintained in RPMI supplemented with 10% fetal bovine
serum, penicillin/streptomycin, and b-mercaptoethanol. The 293T cells
were maintained in DMEM supplemented with 10% fetal bovine serum and
penicillin/streptomycin. Stable APOBEC3-expressing cell lines have been
described and new lines were established using the same methods (Albin
et al., 2010a, 2010b; Hultquist et al., 2011).hors
Figure 5. Wobble Model to Explain the Evolution of the Vif-A3 Interaction
The schematic shows the wobble model for adaptation of the Vif side of the Vif-A3 interface. Each hexagon of the lattice depicts a potential interaction as follows:
ancestral, dark gray; potential, light blue; attenuated, light gray; A3F, orange; and A3G, purple. Themodel predicts that the ancestral Vif-A3 interaction was strong
and consisted of six interaction points (arbitrary number for discussion purposes). Viral transmission to a new host with a larger A3 repertoire results in diminished
but still partly functional interactions. A series of rapid adaptations (possibly most or all in the original new host) restores the strong interaction and results in partly
overlapping interaction surfaces. Then, over a much longer evolutionary period, the combined effect of many independent wobbles triggered by virus or host
genetic changes could result in the present day non-overlapping surfaces of Vif that interact with A3F and A3G. Similar rules would apply to other HIV-1-restrictive
A3s (not shown for simplicity). A strong interactionmay be disrupted by a viral or host amino acid substitution mutation, but the overall interaction can be restored
by a compensatory change in Vif at the same site, nearby, or even to extend the edge of an interaction surface. If this change occurs at a new position, it can be
considered a wobble. A series of wobbles over evolutionary time can account for a shift in the entire interaction surface.HIV-1 Adaptation and Infectivity Studies
The selection protocol was carried out as described in the text and depicted in
Figure 1A. Adapted viruses were selected for molecular characterization if
fourth-passage infectivity exceeded 2% absolute CEM-GFP infectivity for vi-
ruses adapted to A3F QE323-324EK or at least 5% for viruses adapted to
rhA3F. Adapted vif genotypes were identified by preparing genomic DNA
from infected CEM-GFP reporter cells (PureGene), amplifying the vif-vpr region
as described previously (Albin et al., 2010a), and sequencing each PCR prod-
uct (Genewiz). Chromatogramswere inspectedmanually to identify mutations.
Spreading infections were performed as described previously (Albin et al.,
2010a). Single-cycle infectivity studies were done as described using an
HIV-1IIIB Vif-deficient proviral plasmid, APOBEC3F-V5 or an A3F-untagged
construct, and codon-optimized HIV-1IIIB Vif-HA constructs (Albin et al.,
2010a, 2010b; Hultquist et al., 2011).
Immunoblotting
Primary antibodies were mouse (Ms) anti-V5 (Invitrogen), rabbit (Rb) anti-A3F
(NIH AIDS Reagent Program 11474 courtesy of M. Malim), Ms anti-HA.11 (Co-
vance), Ms anti-HIV-1 p24/CA (AIDS Reagent Program 3537 courtesy of B.
Chesebro and K. Wehrly), Ms anti-HIV-1 Vif (AIDS Reagent Program 6459
courtesy of M. Malim), and Ms anti-tubulin (Covance). Secondary antibodies
were donkey anti-Ms IgG-HRP (Jackson Laboratory) and goat anti-Rb IgG-
HRP (Bio-Rad). Additional secondary antibodies were IRdye 800CW goat
anti-Rb (LI-COR Biosciences 827-08365) and Alexa Fluor 680 goat anti-Ms
(Molecular Probes A-21057). Membranes were imaged using commercial
chemiluminescence reagents (Denville Scientific) and film or a LI-COR Odys-
sey instrument. A subset of the LI-COR images were prepared for presentation
using Image J 1.49 (http://rsb.info.nih.gov/ij/download.html).
Statistical Analysis
GraphPad Prism 5.0 was used for statistical analyses (GraphPad). Quantitative
data are presented asmean ±SEM. Statistical significance was determined byCell Retwo-way ANOVA followed by a post hoc Bonferroni test to determine signifi-
cance between or within testing groups. A p value of less than 0.05 was
considered statistically significant.
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